From freedom-to-operate landscape through discovery, patentability, filing, and lifecycle management — the five-stage playbook pharmaceutical companies use to protect a new salt form of a known molecule
Before a single gram of a new salt candidate is synthesized, patent counsel and IP scientists conduct a freedom-to-operate (FTO) analysis: an exhaustive search of granted patents and pending applications that could be infringed by making, using, or selling the proposed product in each target market. For a molecule with an existing composition-of-matter patent, the FTO question is not "can we patent our new salt?" but "can we practice it at all without a license?" — a distinct and prior question that shapes every subsequent decision.
A composition-of-matter (COM) patent on the free-form molecule is the broadest and most commercially valuable patent in a pharmaceutical portfolio — it typically blocks anyone from making, using, or selling the compound in essentially any form, including its salts, esters, solvates, and polymorphs, because COM claims are usually drafted to cover "a compound of Formula I, or a pharmaceutically acceptable salt thereof." This means that even a genuinely novel, non-obvious, and separately patentable salt form can still infringe the underlying COM patent for as long as it remains in force — patentability of the new salt and freedom to practice it are legally independent questions.
FTO searches for a salt-form program specifically probe: • The base COM patent family (all continuations, divisionals, and foreign counterparts) and its expiry date, including any Patent Term Extension (PTE, 35 U.S.C. §156) or Supplementary Protection Certificate (SPC, EU) that can add up to 5 years beyond the standard 20-year term to compensate for regulatory review time. • Existing salt-form patents already claiming the specific counter-ion under consideration (e.g., if the innovator company itself, or a competitor, already claims "the hydrochloride salt of Compound X"). • Polymorph and crystal-form patents, which can independently block a specific solid-state form even after the COM patent expires — this is the mechanism behind many "evergreening" disputes. • Process patents covering specific synthetic routes or crystallization methods that might be the only practical way to manufacture the target form. • Formulation and method-of-use patents (dosing regimens, specific indications) that can extend commercial exclusivity even after composition claims lapse.
Search tools and methodology: professional searchers use Boolean/keyword search combined with chemical structure and Markush-claim searching (CAS SciFinder, Reaxys, Orbit/Questel, PatSnap) because a patent claiming "a pharmaceutically acceptable salt selected from the group consisting of hydrochloride, sulfate, mesylate, besylate, tosylate, phosphate, maleate, fumarate, succinate, tartrate, and citrate" can block a specific salt candidate even though that salt is never made in the examples. Claim charts are then built mapping each granted claim against the proposed product to score blocking risk as clear / caution / blocking, exactly as visualized in the landscape scatter above.
A frequently cited real-world example: after the composition-of-matter patent for omeprazole expired, AstraZeneca's FTO and lifecycle strategy pivoted to the S-enantiomer as its magnesium salt — esomeprazole magnesium (Nexium) — a molecule with independent COM protection because a single, resolved enantiomer of a previously racemic drug can constitute patentable subject matter distinct from the racemate, provided it shows an unexpected property (see Stage 3).
A systematic salt screen exposes the free acid or base to a panel of pharmaceutically acceptable counter-ions across multiple solvents and crystallization conditions, then characterizes every resulting solid form to identify one with a measurable, reproducible, and — critically for patentability — unexpected advantage over the salts already known in the art.
High-throughput salt screening protocol: 1. Counter-ion selection: guided by the ionizable group on the API (basic amine → acid counter-ions: HCl, H2SO4, mesylate/CH3SO3H, besylate, tosylate, maleate, fumarate, citrate, tartrate, phosphate; acidic API → cation counter-ions: Na+, K+, Ca2+, meglumine, choline, tromethamine). Only counter-ions on the FDA's list of generally regarded as safe (GRAS) / Inactive Ingredient Database entries are viable for a marketed product. 2. Parallel crystallization: 24- or 96-well plate format, each well combining free-form API with one equivalent of counter-ion in a chosen solvent, then subjected to cooling, evaporation, or anti-solvent addition. Automated imaging and XRPD (X-ray powder diffraction) screening flags crystalline hits (birefringent under polarized light, sharp XRPD peaks) versus amorphous or oiled-out failures. 3. Scale-up and full characterization of hits: each crystalline salt form is characterized by • XRPD — unique diffraction "fingerprint" (2θ peak positions/intensities) that legally defines a distinct crystal form for patent claims • DSC (differential scanning calorimetry) — melting point, polymorphic transitions, desolvation endotherms • TGA (thermogravimetric analysis) — water/solvent content, hydrate vs. anhydrate confirmation • DVS (dynamic vapor sorption) — hygroscopicity across 0–95% relative humidity; a form absorbing >2% w/w at 60% RH is often considered problematic for manufacturing and storage • Solubility profiling — equilibrium solubility in water, simulated gastric/intestinal fluid (FaSSGF/FaSSIF/FeSSIF), and pH 1.2–7.4 buffers • Accelerated and long-term stability — ICH Q1A(R2) conditions (40°C/75% RH for 6 months; 25°C/60% RH for 12–24 months), monitoring for degradation, form conversion, and moisture uptake
Legal significance of the technical data: patent claims to a specific salt form typically recite the XRPD peak list (e.g., "characterized by an X-ray powder diffraction pattern comprising peaks at 2θ = 6.4, 12.8, 17.1, 19.6, and 24.3° ±0.2°") because this is objectively measurable and distinguishes the claimed form from any other polymorph, solvate, or amorphous version of the same salt — a strategy that has repeatedly withstood validity challenges precisely because it is not merely claiming "the mesylate salt" in the abstract but a specific, reproducible solid-state entity.
The mesylate salt of imatinib (Gleevec/Glivec, Novartis) is a textbook case: Novartis's attempt to patent "beta crystal form" of imatinib mesylate in India was rejected by the Indian Supreme Court in the landmark Novartis v. Union of India (2013) decision under Section 3(d) of the Indian Patents Act, which specifically bars patents on new forms of known substances absent a demonstrated enhancement in therapeutic efficacy — illustrating that jurisdictions differ sharply in how they treat secondary salt/polymorph patents, and FTO/filing strategy must be tailored per territory.
A new salt form is unpatentable if a person of ordinary skill in the art (POSA) would have found it obvious to try, with a reasonable expectation of success, given the prior art. Since KSR v. Teleflex (US Supreme Court, 2007) loosened the rigid "teaching-suggestion-motivation" test, obtaining and defending salt-form patents has required stronger evidence of a genuinely unexpected technical effect — the same substantive standard, differently framed, that the EPO applies through its problem-solution approach.
United States — post-KSR framework: Before KSR v. Teleflex (2007), obviousness rejections generally required the examiner or challenger to identify an explicit "teaching, suggestion, or motivation" (TSM test) in the prior art to combine references. KSR relaxed this into a more flexible, common-sense inquiry, explicitly endorsing an "obvious to try" rationale where: (1) there is a design need or market pressure to solve a known problem, (2) there are a finite number of identified, predictable solutions, and (3) a POSA would have had a reasonable expectation of success in pursuing the known options within their technical grasp. For salt selection, this is dangerous territory: since salt screening against a known, finite list of GRAS counter-ions is exactly the kind of "obvious to try" exercise the POSA is expected to routinely perform. Post-KSR, the USPTO and courts (e.g., Pfizer v. Apotex, Fed. Cir. 2007, regarding amlodipine besylate) have repeatedly held that selecting a salt from a known, finite genus of acceptable counter-ions is prima facie obvious absent evidence to the contrary.
The rebuttal, and the reason Stage 2's characterization data matters so much, is evidence of unexpected results: if the specific chosen salt exhibits a property that a POSA could not have predicted from the prior art — materially superior stability, unexpectedly high solubility or bioavailability relative to other salts in the same screened genus, a non-hygroscopic crystal form where the free base and other salts were hygroscopic, or superior processability — this can overcome an obviousness rejection/challenge even under KSR's expansive standard. The strength of this evidence is judged by (a) whether the comparison is to the closest prior art salt (not a cherry-picked weak comparator), (b) whether the magnitude of the difference is significant and reproducible, and (c) whether the specification adequately discloses and supports the comparative data at the time of filing — after-the-fact declarations are given less weight than data in the original application.
European Patent Office — problem-solution approach: The EPO's structured three-step test for inventive step (Art. 56 EPC) asks: (1) what is the "closest prior art"? (2) what "objective technical problem" is solved by the claimed invention relative to that closest prior art? (3) would the POSA, starting from the closest prior art and faced with that objective technical problem, have arrived at the claimed solution as a matter of course ("could-would" approach)? For salt-form claims, EPO examiners routinely reformulate the objective technical problem based on the actual demonstrated effect (e.g., "to provide a salt form with improved storage stability") and then ask whether the skilled person, motivated to solve that problem, would have been led to select the specific claimed salt with a reasonable expectation of success — again turning centrally on whether the technical effect was predictable or genuinely surprising.
Both regimes converge on the same practical lesson for a salt-form patent program: front-load robust, well-controlled comparative data (ideally head-to-head against the two or three most similar/closest prior-art salts, not merely against the free base) directly in the patent specification as filed, because this evidence is the primary defense against an obviousness attack in litigation or opposition.
Secondary-patent ("evergreening") scrutiny has intensified globally: the EU's 2023 pharmaceutical legislation reform proposals, India's Section 3(d), and heightened US Patent Trial and Appeal Board (PTAB) inter partes review activity all specifically target low-inventive-merit follow-on patents on known molecules. A salt-form patent supported only by routine screening data and no demonstrated unexpected technical effect is now one of the most frequently challenged and invalidated categories of pharmaceutical patent.
A well-constructed salt-form patent application is not a single claim but a layered portfolio: composition-of-matter claims to the new salt itself, crystal-form/polymorph claims to specific characterized solid states, process claims to the manufacturing/crystallization route, and formulation or method-of-treatment claims — filed first as a domestic priority application and then extended internationally through the Patent Cooperation Treaty (PCT) within strict statutory deadlines.
Layered claim architecture for a salt-form patent family: 1. Composition-of-matter claims — "A [salt name] of Compound X, or a hydrate or solvate thereof" — the broadest and most valuable claim type, ideally supported by data showing the salt itself (independent of crystal form) has properties distinguishing it from the free form and other known salts. 2. Crystal-form/polymorph claims — narrower claims reciting specific XRPD peaks, DSC onset temperatures, and/or Raman/solid-state NMR signatures that define a particular reproducible solid-state form of the salt; these can survive even if the broader composition claim is challenged, and can extend protection independently since new polymorphs of an already-known salt can sometimes be discovered and claimed later, creating a second layer of exclusivity. 3. Process claims — covering a specific, non-obvious crystallization or salt-formation process (particular solvent system, seeding protocol, cooling profile) that reliably produces the claimed form; valuable when the form itself might be hard to defend but the only practical manufacturing route is protectable. 4. Formulation and method-of-use claims — covering specific tablet/capsule formulations, dosing regimens, or new therapeutic uses enabled by the improved properties of the new salt (e.g., a once-daily regimen enabled by improved bioavailability).
Filing timeline mechanics: • Priority filing (month 0): first patent application filed in a home jurisdiction (e.g., US provisional application, or a first-filing under the relevant national/regional office) establishing the priority date — the critical date against which all prior art and novelty is assessed. • PCT filing (by month 12): under the Paris Convention, an applicant has 12 months from the priority filing to file a PCT international application (or direct national/regional applications) claiming that priority date. A single PCT application effectively "reserves" the right to seek patent protection in all ~157 PCT contracting states. • International search report and written opinion (~month 16): WIPO-administered International Searching Authority issues a search report and preliminary (non-binding) opinion on novelty/inventive step/industrial applicability. • International publication (month 18): the PCT application publishes, entering the prior art. • Optional Chapter II demand (by month 22): applicant may request an International Preliminary Examination, extending the national-phase deadline. • National phase entry (month 30, or month 31 with Chapter II demand): the applicant must enter national/regional phase in each specific country or region where protection is actually sought (USPTO, EPO, JPO, CNIPA, etc.), paying separate fees and often needing local counsel and translations — this is the point of substantial, jurisdiction-specific cost, so companies use the PCT's 30-month runway to gather additional data (e.g., completed stability studies, clinical PK data confirming the bioavailability advantage) before committing to the expensive national-phase filings. • Substantive examination and grant (typically 2–5 years post national-phase entry, jurisdiction-dependent): each national/regional office independently examines novelty and inventive step; prosecution often includes responding to obviousness rejections using the comparative data developed in Stage 2–3.
Because composition-of-matter, polymorph, process, and formulation claims are typically filed as related but legally distinct patents (sometimes even as separate priority filings staggered by months or years as new data becomes available), a mature salt-form portfolio often comprises 5–15 individual patent families with staggered priority and expiry dates — the structural basis for the lifecycle management strategy in Stage 5.
Once a salt-form product is on the market, patent lifecycle management becomes a defensive and strategic discipline: monitoring for generic Paragraph IV challenges under the Hatch-Waxman Act, litigating or settling those challenges, layering pediatric and other exclusivity extensions, and planning for the eventual, largely unavoidable transition to generic competition at the "patent cliff."
The Hatch-Waxman Act (1984) created the modern US generic drug pathway (Abbreviated New Drug Application, ANDA) in exchange for patent term restoration for innovators. A generic applicant referencing a listed drug must certify against each patent listed in the FDA's Orange Book as one of four options; a "Paragraph IV" certification asserts that the listed patent is invalid, unenforceable, or will not be infringed by the generic product — and filing a Paragraph IV certification is itself defined by statute as an act of patent infringement, immediately giving the innovator the right to sue.
If the innovator sues within 45 days of receiving notice of the Paragraph IV certification, the FDA is automatically barred from approving the generic ANDA for 30 months (or until a court decision, if earlier) — the "30-month stay." This is a central lifecycle-management lever: a portfolio with multiple staggered patents (composition, salt, polymorph, formulation, method-of-use) means multiple potential Paragraph IV certifications and multiple opportunities to trigger stays, litigate, and negotiate settlements, effectively extending commercial exclusivity well past the expiry of the original composition-of-matter patent.
The first generic applicant to file a substantially complete ANDA with a Paragraph IV certification is awarded 180 days of generic marketing exclusivity (during which the FDA may not approve subsequent generic ANDAs), a valuable prize that drives aggressive early generic challenges — often against a company's newest, most vulnerable secondary patents (salt/polymorph claims) rather than the (usually already-expired or soon-expiring) original composition patent.
Exclusivity stacking available to extend commercial life beyond the base patent term: • Patent Term Extension (PTE, 35 U.S.C. §156): up to 5 years added to ONE patent per product to compensate for FDA regulatory review time, capped so total post-approval market exclusivity does not exceed 14 years from approval. • Pediatric exclusivity (BPCA): +6 months added to the term of every unexpired patent AND regulatory exclusivity on the product, awarded for completing FDA-requested pediatric studies — one of the single most valuable and commonly used levers because of its "stack on everything" effect. • New Chemical Entity (NCE) exclusivity: 5 years regulatory exclusivity from first approval (independent of patents); New Clinical Investigation exclusivity: 3 years for new indications/formulations/dosing supported by new clinical trials — relevant when a new salt-form product itself qualifies for its own NCE-adjacent exclusivity period. • Orphan drug exclusivity: 7 years for approved orphan indications, layered on top of patent protection where applicable.
Real-world "patent cliff" case study — omeprazole/esomeprazole: AstraZeneca's omeprazole (Prilosec) composition-of-matter patent protection lapsed in the late 1990s/2000, precipitating a classic patent cliff and rapid generic/OTC erosion of the franchise. The company's lifecycle response — resolving the racemate into the S-enantiomer and reformulating as esomeprazole magnesium (Nexium), independently patentable due to demonstrated pharmacokinetic differences from the racemate — successfully extended proton-pump-inhibitor franchise exclusivity by roughly a decade, and is now the canonical business-school and law-school case study in both the commercial power and the legal limits (repeatedly challenged, and only partly upheld, in litigation) of enantiomer/salt-based patent lifecycle management.
Because Paragraph IV litigation typically targets the weakest link in a patent portfolio first, companies pursuing a salt-form lifecycle strategy should expect their newest, least-litigated secondary patents (the very patents built in Stages 2–4 of this workflow) to face earlier and more aggressive generic challenges than the original, well-tested composition-of-matter patent — robust unexpected-effect data from Stage 2/3 is therefore not just a prosecution requirement but the primary litigation defense years later.